title: Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling.
abstract: Patients with amyotrophic lateral sclerosis (ALS) have evidence of chronic inflammation demonstrated by infiltration of the gray matter by inflammatory macrophages, IL17A-positive T cells, and mast cells. Increased serum levels of IL6 and IL17A have been detected in sporadic ALS (sALS) patients when compared to healthy controls. Herein we investigate, in peripheral blood mononuclear cells (PBMCs), the baseline transcription of genes associated with inflammation in sALS and control subjects and the impact of the IL6 receptor (IL6R) antibody (tocilizumab) on the transcription and/or secretion of inflammation factors (e.g. cytokines) stimulated by the apo-G37R superoxide dismutase (SOD1) mutant. At baseline, PBMCs of four sALS patients (Group 1) showed significantly increased expression of TLR2 and CD14; ALOX5, PTGS2 and MMP1; IL1α, IL1β, IL6, IL36G, IL8 and TNF; CCL3, CCL20, CXCL2, CXCL3 and CXCL5. In four other sALS patients (Group 2), most of the genes just mentioned were expressed at near control levels and a significant decrease in the expression of PPARG, PPARA, RARG, HDAC4 and KAT2B; IL6R, IL6ST and ADAM17; TNFRSF11A; MGAT2 and MGAT3; PLCG1; CXCL3 were detected. Apo-G37R SOD1 up regulated the transcription of cytokines (e.g. IL1α/β, IL6, IL8, IL36G), chemokines (e.g. CCL20; CXCL3, CXCL5), and enzymes (e.g. PTGS2 and MMP1). In vitro, tocilizumab down regulated the transcription of many inflammatory cytokines, chemokines, enzymes, and receptors, which were up regulated by pathogenic forms of SOD1. Tocilizumab also reduced the secretion of the pro-inflammatory cytokines IL1β, IL6, TNFα, GM-CSF, IFNγ, and IL17A by Group 1 PBMCs. Finally, sALS patients had significantly higher concentrations of IL6, sIL6R and C-reactive protein in the cerebrospinal fluid when compared to AD patients. This pilot study demonstrates that in vitro tocilizumab suppresses many factors that drive inflammation in sALS patients, with possible increased efficacy in Group 1 ALS patients.
authors: Department of Surgery, David Geffen School of Medicine at UCLA 650 Charles E. Young Dr. South, Los Angeles, CA 90095-1735, USA.
authors: Mathew T
authors: MT
authors: Mizwicki
authors: Milan
authors: M
authors: Fiala
authors: Larry
authors: L
authors: Magpantay
authors: Najib
authors: N
authors: Aziz
authors: James
authors: J
authors: Sayre
authors: Guanghao
authors: G
authors: Liu
authors: Avi
authors: A
authors: Siani
authors: Derrick
authors: D
authors: Chan
authors: Otoniel
authors: O
authors: Martinez-Maza
authors: Madhuri
authors: M
authors: Chattopadhyay
authors: Antonio
authors: A
authors: La Cava
keywords: IL6 receptor signaling; Tocilizumab; amyotrophic lateral sclerosis (ALS); chronic inflammation
references: Brain Res. 1998 Jan 12;780(2):356-9
references: 9507194
references: Am J Neurodegener Dis. 2012;1(1):60-74
references: 22787561
references: Biol Psychiatry. 2010 Nov 15;68(10):930-41
references: 20692646
references: Expert Opin Biol Ther. 2012 Sep;12(9):1277-89
references: 22849354
references: Brain. 2011 May;134(Pt 5):1293-314
references: 21596768
references: J Biol Chem. 2011 Dec 16;286(50):42959-70
references: 21990364
references: Neurosci Lett. 1997 Dec 12;239(1):29-32
references: 9547164
references: Curr Opin Rheumatol. 2011 May;23(3):273-7
references: 21427577
references: Annu Rev Immunol. 2009;27:485-517
references: 19132915
references: Expert Opin Ther Targets. 2012 Feb;16(2):225-36
references: 22324903
references: Expert Opin Investig Drugs. 1997 Mar;6(3):237-66
references: 15989626
references: Mod Rheumatol. 2010 Jun;20(3):222-32
references: 20221663
references: N Engl J Med. 2009 Aug 27;361(9):888-98
references: 19710487
references: J Immunol. 2009 Jan 1;182(1):613-22
references: 19109195
references: Arthritis Res Ther. 2011;13(5):R141
references: 21884601
references: Biochim Biophys Acta. 2011 May;1813(5):878-88
references: 21296109
references: Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13046-50
references: 20616033
references: Ann Neurol. 2004 Feb;55(2):221-35
references: 14755726
references: Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Dec;5(4):213-9
references: 15799549
references: J Neuroinflammation. 2010 Nov 09;7:76
references: 21062492
references: Neurosci Lett. 1995 Dec 29;202(1-2):17-20
references: 8787820
references: J Clin Invest. 2012 Sep;122(9):3063-87
references: 22863620